Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc. is a late clinical-stage therapeutics company that develops and aims to commercialize new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company's neuroscience pipeline includes five clinical-stage intranasal pherine product candidates, each with a novel neurocircuitry-focused proposed mechanism of action and at least one positive clinical study in its targeted patient population. These intranasal pherine product candidates are designed to rapidly, specifically, and selectively bind to peripheral receptors in human nasal chemosensory neurons and activate neurocircuits that are believed to regulate brain areas, without requiring systemic absorption or uptake into the brain for therapeutic benefits. Vistagen Therapeutics, Inc.'s most advanced intranasal pherine product candidate, fasedienol, is currently in a U.S. Phase 3 development program for the acute treatment of social anxiety disorder. Other product candidates include itruvone, which is being developed for the treatment of major depressive disorder; refisolone, for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause; PH15, for the improvement of psychomotor impairment due to mental fatigue; and PH284, for the treatment of cancer cachexia. Social anxiety disorder affects over 30 million adults in the U.S. and typically has an onset early in life, with a reported mean duration of about 20 years.